Heart rhythm · 2026
Hemolysis and kidney injury after catheter ablation for atrial fibrillation: Microsecond vs nanosecond pulsed field ablation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ding Lei, Xiang Bing, Qi Yingjie, Liu Yuandong, Zhang Kuo, Jiang Zihan, Yu Fengyuan, Zhang Hongda, Tang Min
Аннотация
BACKGROUND: Microsecond pulsed field ablation (PFA) (microPFA) has been associated with postablation hemolysis, whereas evidence for the use of nanosecond PFA (nanoPFA) remains limited.
OBJECTIVE: This study aimed to compare hemolysis and acute kidney injury (AKI) after microPFA, nanoPFA, and radiofrequency ablation (RFA).
METHODS: We included 323 patients who underwent atrial fibrillation ablation at a high-volume Chinese center, including microPFA (n = 186), nanoPFA (n = 65), or RFA (n = 72). Pulmonary vein isolation was performed with or without additional ablation. Hemolysis and renal biomarkers were measured at baseline, procedure end, and 24 hours after the procedure.
RESULTS: PFA produced obvious hemolysis, which was not observed with RFA. Postablation bilirubin, lactate dehydrogenase (LDH), and free hemoglobin increased and haptoglobin decreased with PFA. LDH (229.0 ± 50.6 vs 198.4 ± 33.8 IU/L; P < .001) and free hemoglobin levels (289.3 ± 45.1 vs 263.7 ± 55.0 ng/mL; P = .043) were higher with microPFA than with nanoPFA after multivariable adjustment. Hemoglobin decline and hemoglobin drop of >20 g/L occurred more often after microPFA (44.1% and 58.1%) than after RFA (22.2% and 27.8%) and nanoPFA (18.5% and 20.0%). AKI was uncommon (microPFA 3; nanoPFA 1; RFA 0). In microPFA, hemolysis scaled with delivery number (LDH ratio r = 0.26; 95% confidence interval 0.10-0.40; bilirubin ratio r = 0.15; 95% confidence interval 0-0.29), whereas no dose-dependent association was detected with nanoPFA.
CONCLUSION: PFA for atrial fibrillation typically induced hemolysis; however, the application-related dose effect was observed in microPFA, but not in nanoPFA. NanoPFA was associated with lower hemolysis indices, whereas severe anemia and AKI may be rare. Larger studies are needed to confirm modality differences, define clinical impact, and optimize application titration.
OBJECTIVE: This study aimed to compare hemolysis and acute kidney injury (AKI) after microPFA, nanoPFA, and radiofrequency ablation (RFA).
METHODS: We included 323 patients who underwent atrial fibrillation ablation at a high-volume Chinese center, including microPFA (n = 186), nanoPFA (n = 65), or RFA (n = 72). Pulmonary vein isolation was performed with or without additional ablation. Hemolysis and renal biomarkers were measured at baseline, procedure end, and 24 hours after the procedure.
RESULTS: PFA produced obvious hemolysis, which was not observed with RFA. Postablation bilirubin, lactate dehydrogenase (LDH), and free hemoglobin increased and haptoglobin decreased with PFA. LDH (229.0 ± 50.6 vs 198.4 ± 33.8 IU/L; P < .001) and free hemoglobin levels (289.3 ± 45.1 vs 263.7 ± 55.0 ng/mL; P = .043) were higher with microPFA than with nanoPFA after multivariable adjustment. Hemoglobin decline and hemoglobin drop of >20 g/L occurred more often after microPFA (44.1% and 58.1%) than after RFA (22.2% and 27.8%) and nanoPFA (18.5% and 20.0%). AKI was uncommon (microPFA 3; nanoPFA 1; RFA 0). In microPFA, hemolysis scaled with delivery number (LDH ratio r = 0.26; 95% confidence interval 0.10-0.40; bilirubin ratio r = 0.15; 95% confidence interval 0-0.29), whereas no dose-dependent association was detected with nanoPFA.
CONCLUSION: PFA for atrial fibrillation typically induced hemolysis; however, the application-related dose effect was observed in microPFA, but not in nanoPFA. NanoPFA was associated with lower hemolysis indices, whereas severe anemia and AKI may be rare. Larger studies are needed to confirm modality differences, define clinical impact, and optimize application titration.